EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insights into Early Interactions on Innovative Developments with European Regulators

David W Uster, Valentina Cordo', Emmanuel Cormier, Falk Ehmann

Therapeutic Innovation & Regulatory Science · 2024-11 · 58 (6) · 1108-1119

DOI: 10.1007/s43441-024-00686-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 30.08.2024. Verfasst von David W Uster und 3 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency (EMA), Amsterdam, The Netherlands. uster.dav@gmail.com. Hauptthemen laut MEDLINE: Drug Development. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The European Medicines Agency Innovation Task Force (ITF) acts as early point of contact for medicine and technology developers to enable innovation during early drug development stages through ITF briefing meetings.

Aim

To reflect on the current pace of innovation and to assess the potential of ITF stakeholder interactions, a comprehensive analysis of the ITF briefing meetings held between 2021 and 2022 was conducted with a focus on individual questions raised by the developers and the related feedback provided by the European regulators.

Methods

Questions raised during ITF briefing meetings were extracted and categorised into main and sub-categories, revealing different themes across the whole medicine development process such as manufacturing technologies, pre-clinical developments, and clinically relevant questions.

Results

There was positive feedback from regulators who gave initial guidance in 85% of the answers, provided concrete examples in 20% of the answers and recommended to continue discussions through additional regulatory procedures in 22% of the answers.

Conclusion

This analysis frames the content and the type of topics discussed during ITF briefing meetings. Moreover, it describes the type of regulatory feedback provided to medicine developers and identified potential for improvement of these early interactions. Therefore, this analysis emphasises the role of ITF briefing meetings in fostering innovation in medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentEuropeHumansAdvisory Committees

Stichwörter der Autor:innen

Drug developmentEMAInnovationMethodologiesRegulatory supportTherapies

Autor:innen und Institutionen

  • European Medicines Agency (EMA), Amsterdam, The Netherlands. uster.dav@gmail.com.
  • European Medicines Agency (EMA), Amsterdam, The Netherlands. valentina.cordo@ema.europa.eu.
  • European Medicines Agency (EMA), Amsterdam, The Netherlands.

Zitieren

APA

Uster, D. W., Cordo', V., Cormier, E., & Ehmann, F. (2024). Insights into Early Interactions on Innovative Developments with European Regulators. Therapeutic Innovation & Regulatory Science, 58(6), 1108-1119. https://doi.org/10.1007/s43441-024-00686-7

Vancouver

Uster DW, Cordo' V, Cormier E, Ehmann F. Insights into Early Interactions on Innovative Developments with European Regulators. Therapeutic Innovation & Regulatory Science. 2024;58(6):1108-1119. doi:10.1007/s43441-024-00686-7

BibTeX
@article{Uster2024,
  author = {Uster, David W and Cordo', Valentina and Cormier, Emmanuel and Ehmann, Falk},
  title = {Insights into Early Interactions on Innovative Developments with European Regulators},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2024},
  volume = {58},
  number = {6},
  pages = {1108--1119},
  doi = {10.1007/s43441-024-00686-7}
}
Kostenlos starten →